Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;18(9):577-83.
doi: 10.1016/j.neo.2016.07.010.

Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes

Laura J Tafe  1 , Kirsten J Pierce  2 , Jason D Peterson  2 , Francine de Abreu  2 , Vincent A Memoli  2 , Candice C Black  2 , Jason R Pettus  2 , Jonathan D Marotti  2 , Edward J Gutmann  2 , Xiaoying Liu  2 , Keisuke Shirai  3 , Konstantin H Dragnev  3 , Christopher I Amos  4 , Gregory J Tsongalis  2
Affiliations

Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes

Laura J Tafe et al. Neoplasia. 2016 Sep.

Abstract

Detection of somatic mutations in non-small cell lung cancers (NSCLCs), especially adenocarcinomas, is important for directing patient care when targeted therapy is available. Here, we present our experience with genotyping NSCLC using the Ion Torrent Personal Genome Machine (PGM) and the AmpliSeq Cancer Hotspot Panel v2. We tested 453 NSCLC samples from 407 individual patients using the 50 gene AmpliSeq Cancer Hotspot Panel v2 from May 2013 to July 2015. Using 10 ng of DNA, up to 11 samples were simultaneously sequenced on the Ion Torrent PGM (316 and 318 chips). We identified variants with the Ion Torrent Variant Caller Plugin, and Golden Helix's SVS software was used for annotation and prediction of the significance of the variants. Three hundred ninety-eight samples were successfully sequenced (12.1% failure rate). In all, 633 variants in 41 genes were detected with a median of 2 (range of 0 to 7) variants per sample. Mutations detected in BRAF, EGFR, ERBB2, KRAS, NRAS, and PIK3CA were considered potentially actionable and were identified in 237 samples, most commonly in KRAS (37.9%), EGFR (11.1%), BRAF (4.8%), and PIK3CA (4.3%). In our patient population, all mutations in EGFR, KRAS, and BRAF were mutually exclusive. The Ion Torrent Ampliseq technology can be utilized on small biopsy and cytology specimens, requires very little input DNA, and can be applied in clinical laboratories for genotyping of NSCLC. This targeted next-generation sequencing approach allows for detection of common and also rare mutations that are clinically actionable in multiple patients simultaneously.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of sample types that were successfully sequenced (n= 398). LN – lymph node; FNA – Fine needle aspiration.
Figure 2
Figure 2
Number of cases with variants detected in the respective 50 genes included in the NGS assay.
Figure 3
Figure 3
Clinically actionable mutations identified.
Figure 4
Figure 4
Co-occurrence of clinically actionable mutations.
See this image and copyright information in PMC

References

    1. Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A.G., editors. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. IAEC; Lyon: 2015. - PubMed
    1. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550. - PMC - PubMed
    1. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525. - PMC - PubMed
    1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828–860. - PMC - PubMed
    1. National Comprehensive Cancer Network . 2015. NCCN Guidelines Version 4.